Skip directly to content

NEWS

JOB OPPORTUNITY:  Director of Finance & Operations
December 14, 2018 – We’re seeking a highly motivated and organized Director of Finance and Operations to manage and help execute its operations, with a strong focus on building systems for more efficient work and communication within and across the organization. This position will report to the Executive Director, and be based in New York City.

December 2018 TAG Update
December 13, 2018 – We accomplished some great things in 2018, and they were made possible by our generous donors. Download your own copy of TAG Update to read all about them.

Fall, 2018 TAGline: Bringing Down the House on Intellectual Property and Access
This issue of TAGline dives deep into the rhetoric and realities of intellectual property  (IP)  protections  and  the current wave of political shenanigans on critical drugs, surfacing the fundamental lies and vested interests that deny medication to those in need in the United States and around the world.

Comment in Response to Proposed Rulemaking: Inadmissibility on Public Charge Grounds
December 7, 2018 – On October 10, 2018, the Trump Administration proposed sweeping regulations that would put the health and wellbeing of millions of families at risk. TAG is strongly opposed  to these proposed changes; read the comment we submitted on December 7.

Campaign for Sofosbuvir's 5th Birthday
December 6, 2018 – People living with hepatitis C, access to medicines activists, and the medical community around the world “marked” the fifth birthday of the first all-oral, one dose per day cure sofosbuvir (Sovaldi®), launched by Gilead Sciences. However, despite being a breakthrough cure, the vast majority of people still haven't been treated…

Hepatitis Cure, Sofosbuvir, Turns 5 Years Old: The Vast Majority of People Still Have Not Been Treated
December 6, 2018 – Advocates scandalized that Gilead's hepatitis C profits have raked in US$25.8 billion, which could have treated everyone while still earning US$16 billions in profits. 

Tuberculosis Research Funding Trends 2005 – 2017
December 3, 2018 – Global funding for tuberculosis (TB) research climbed to a previously unreported high of USD $772 million in 2017, according to a report released today by Treatment Action Group (TAG) and the United Nations-hosted Stop TB Partnership.

Treatment Action Group Statement on the Reported Birth of Twins with Edited CCR5 Genes
November 26, 2018 – Treatment Action Group (TAG) decries the claimed use of CRISPR technology to edit genes for the HIV co-receptor CCR5 in human embryos for implantation. 

TAG Comment on Penalties Relating to the ClinicalTrials.gov Data Bank
November 20 – Read TAG's comment on The Food and Drug Administration (FDA) Notice: Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank; Draft Guidance for Food and Drug Administration Staff, Responsible Parties, and Submitters of Certain Applications and Submissions to the FDA. 

Research Toward a Cure
November 16, 2018  A regularly updated listing of clinical trials and observational studies related to the research effort to cure HIV infection.

Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults
November 14, 2018 – The research effort to develop a cure for HIV infection includes clinical studies in which people with HIV are asked to temporarily interrupt antiretroviral therapy. Analytical treatment interruptions (ATIs), as they are called, go against the current standard of care and may pose risks. TAG has generated an updated set of community recommendations on the use of ATIs in research, with the aim of contributing to the discussion regarding maximizing safety and minimizing risk for participants.

OPEN APPEAL: URGENT NEED TO ADDRESS THE GLOBAL FUND PROCUREMENT CLIFF FOR TB
October 26, 2018 — The immense worldwide investment of the Global Fund to Fight AIDS, TB and Malaria (GFATM) has proven effective to ensure increased access to an affordable, high-quality, and sustained supply of TB drugs.

Rapid Shift From Global To National Purchase of TB Drugs Increases Risk of Stockouts and Use of Drugs of Unknown Quality
October 26, 2018 — Global activists at the 49th Union Conference on Lung Health in The Hague opened up a pop-up TB drug warehouse to warn about the dire public health consequences of a rushed shift from Global Fund supported pooled procurement of tuberculosis (TB) drugs and other health products to domestic funding and national procurement systems.

Activists Urge National TB Programs and Treatment Providers To Discontinue Use of Harmful Injectable Agents in TB Treatment
October 25, 2018 – Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in treatment regimens for drug-resistant tuberculosis, in favor of newer, safer World Health Organization (WHO)-recommended treatments.

Activists Call on Countries and Donors To Immediately Scale Up Use of Life-Saving TB LAM Test
October 25, 2018 – On the first day of the 49th Union World Conference on Lung Health, activists from around the globe kicked off a week of actions by calling on countries, development partners, and donors to end the unacceptable rates of death caused by tuberculosis (TB) in people living with HIV by immediately scaling up the use of TB LAM testing.

National TB Checklist
October 19, 2018 – Access to quality diagnosis, treatment, and prevention for tuberculosis (TB) is a human right. Are the necessary tests, treatments, vaccines, services and policies available where you live or work? Our new checklist lays out simply the core elements of an adequate TB response.

Reality Check: The Price of Bedaquiline
October 16, 2018 – Bedaquiline is now recommended as a core part of drug-resistant TB treatment, but price is a major concern to ensuring all who need treatment with bedaquiline receive it. The public has made significant investments in the development and introduction of bedaquiline, which should be reflected in the price.

Right to Science Submission, October 2018
October 16, 2018 – The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).

TB, Human Rights, and Universal Periodic Review
October 12, 2018 – Universal Periodic Review (UPR) is a process through which the human rights record of each United Nations member state is reviewed by other countries every five years. As a civil society organization, TAG regularly writes and submits these UPR reports analyzing the TB situations in UN member states, and you can review our UPR reports on this page.

An Activists' Guide to Bedaquiline
October 12, 2018 – This guide — updated from the original version put out by Treatment Action Group in 2013 — summarizes updated efficacy, safety, and access information about bedaquiline, an essential medication in the treatment of multidrug-resistant TB (MDR-TB).

TAG Cofounder Gregg Gonsalves Receives 2018 MacArthur Fellowship
October 4, 2018 – Treatment Action Group congratulates TAG cofounder Gregg Gonsalves and Yale University Assistant Professor Gregg Gonsalves on receiving a 2018 MacArthur Fellowship.

Activists: Call On Your Countries To Use BDQ-Based Regimens to Treat TB
September 28, 2018 – Just download this easy-to-use letter template from GCTA, TAG, and DR-TB STAT.

What's Missing from the UN Political Declaration on Tuberculosis?
September 26, 2018 – World leaders have gathered for the UN High Level Meeting to ratify a plan to fight TB – but TAG is one of organizations who signed on to a statement detailing what we think is missing from that official statement.

Research Priorities for Pediatric Tuberculosis
September 24, 2018 – An estimated one million children develop tuberculosis (TB) disease each year, and a further 7.5 million are exposed and in need of evaluation and treatment to mitigate the risk of developing TB. Yet, existing approaches to prevent, diagnose and treat TB either do not meet the needs of children or are not available where they are needed the most.

Funding for TB Research: Recent Momentum Must Inspire Bold Commitments
September 24, 2018 – In advance of the first-ever United Nations High-Level Meeting on Tuberculosis (TB), a new brief from Treatment Action Group (TAG) — Funding for TB Research: Recent Momentum Must Inspire Bold Commitments — shows that global funding for TB research and development (R&D) reached a new high of USD $767.8 million in 2017.

Research in Action Awards 2018
September 18, 2018 – TAG is honored to host our annual Research in Action Awards on November 15 here in New York City. Please join us for this powerful experience, which will celebrate our 26 years of activism and progress. We're honoring Journalist Masha Gessen, Dr. Margaret  Hamburg, and Film Producer Joy Tomchin, and acclaimed American artist Zoe Leonard has donated this year's very special limited art edition. Get your tickets now!

Exciting Changes on the TAG Team
September 4, 2018 – Read Mark Harrington’s piece on very important staff additions and changes that will have a significant impact in TAG’s TB, HCV, HIV, policy and development work.

Open Letter from Civil Society to the Regulatory Authority in South Africa
August 23, 2018 – in an open letter to the South African Health Products Regulatory Authority (SAHPRA), TAG joined South African and global civil society partners in calling attention to the urgent need to register essential medicines for the treatment and prevention of tuberculosis in South Africa.

Webinar: Implementing an Injectable-Free Regimen for Drug-Resistant Tuberculosis
August 22, 2018 – Treatment Action Group (TAG), the Global Tuberculosis Community Advisory Board (CAB), the DR-TB Scale-Up Treatment Action Team (DR-TB STAT), and TB Proof hosted this webinar on Thursday, August 16, 2018 to discuss the evidence for and importance of using bedaquiline-based, injectable-free regimens for drug-resistant tuberculosis (DR-TB).

The TB CAB and TAG welcome WHO recommendation of injectable-free regimens for the treatment of drug-resistant TB
August 17, 2018 – Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) have issued a response to the World Health Organization (WHO) Rapid Communication announcing key changes to its treatment guidelines for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB).

U.S. TB and Access to Medicines Stakeholder Letter to U.S. Amb. Nikki Haley on HLM Declaration Negotiations
August 8, 2018 – In response to the reopening of negotiations on the TB High-Level Meeting (HLM) political declaration, a coalition of U.S.-based civil society stakeholders have submitted a letter to U.S. Ambassador to the UN, Nikki Haley, urging a diplomatic solution to the contentious provisions on access to medicines.

Comment in Opposition to Citizenship Question on 2020 U.S. Census
August 3, 2018 –
As a member of New York Counts 2020, Treatment Action Group submitted this comment to express strong opposition to the addition of a citizenship question to the 2020 U.S. Census form. 

TAG Applauds New York Governor for Committing to Statewide Hepatitis C Elimination Task Force, Action Puts NY at Forefront of Hepatitis C Elimination Efforts in the US
July 27, 2018, New York, NY –  In major step forward, New York State Governor Andrew Cuomo delivered on his earlier commitment to eliminate hepatitis C virus (HCV) with today’s announcement of his intention to appoint a statewide Hepatitis C Elimination Task Force.

Migrants’ Inclusion Central to Achieving HIV and Hepatitis C Targets by 2030
July 26, 2018, Amsterdam, The Netherlands – The European African Treatment Advocates Network (EATAN), in partnership with Treatment Action Group (TAG) and other migrant-focused organizations, hosted the European African HIV & Hepatitis C Virus (HCV) Community Summit 2018.

Additional Translations of Two TB Activist's Guides
July 24, 2018 – Spanish translations of An Activist’s Guide to Tuberculosis Diagnostic Tools and An Activist’s Guide to Tuberculosis Drugs are now available.

Activists Call on Countries and Donors to Immediately Scale Up Use of Life-Saving TB LAM Test
July 22, 2018 – At the TB 2018 pre-conference held on Sunday 22 July 2018, before the International AIDS Conference in Amsterdam, activists from around the globe called on their countries, development partners, and donors, to end the unacceptable death rates caused by TB in people living with HIV by immediately scaling up the use of TB LAM testing.

Strengthening TB Research in NIAID's Tuberculosis Strategic Plan
July 17, 2018 – Treatment Action Group (TAG) submitted comments to the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) in response to a public request for information (RFI) to inform NIAID's Tuberculosis Strategic Plan on supporting TB research and development (R&D).

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications
July 16, 2018 – Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.

Activists Call on Johnson & Johnson to Drop the Price of Bedaquiline
July 12, 2018 – TAG and activist colleagues expressed concern that the high price of bedaquiline — a crucially important drug for treating drug-resistant TB and one that is now being used in South Africa to replace the hearing-loss causing injectable drugs — will limit its uptake. The activists called on Johnson & Johnson, the maker of bedaquiline, to drop the price in all markets to $32 a month or lower (no more than $192 for six months), and  develop further volume-based price reductions at pre-set benchmarks, to both allow for maximal affordability and further incentivize rapid uptake of bedaquiline. 

Mark Harrington of TAG and Dr. Demetre Daskalakis of NYC Health Dept. Respond to NY Times Opinion Piece About PrEP
July 5, 2018 – Read Mark and Demetre's response to The New York Times June 26 opinion piece, "The End of Safe Gay Sex?"

Videos from a TB Research Briefing for UN Missions, “The Vital Role of Research for TB Elimination"
July 5, 2018 – This briefing, held in New York City on June 4, 2018 and hosted by Treatment Action Group, Médecins Sans Frontières, the Stop TB Partnership, the Union, in partnership with the the Permanent Missions of Brazil and India to the United Nations, the World Health Organization and the United Nations Development Programme, to provide information and an opportunity for discussion on the importance of investing in the full spectrum of TB research and adopting principles to guide research to ensure efficiency and equitable access.

TAG Welcomes Price Reductions For TB Medicines
June 19, 2018 – Countries and donors must do more to ensure all people with TB have access; further price reductions for newer medicines required.

Sign-On Letter: Advocacy to End Peace Corps HIV Dismissals
May 15, 2018 – Sign our letter to Dr. Josephine Olsen, Director of the Peace Corps, about their policies and practices regarding volunteers newly diagnosed with HIV.

Webinar: Ending the Epidemic - Building Effective Collaboration between Community Advocates and Health Departments
May 15, 2018 – Register now for this free webinar on May 31.

Affordable Medicines Now Conference: June 27–29, 2018
Affordable Medicines Now is a training conference designed to build skills, knowledge and community among the activists who power the movement for affordable medicines at the state, federal, and international levels.

Tools To Help Support Activists in Engaging National Policy Makers on TB
May 3, 2018 – We just added two great new tools: a brief on TB R&D needs and key asks, and a brief on pediatric TB needs and key asks.

Webinar: Ending the Epidemic - Update on Implementing the New York State Blueprint
April 25, 2018 – On April 13th, 2018 TAG and Housing Works hosted a discussion with New York EtE leadership to review recent successes in implementing the Blueprint, assess policy advocacy for the coming year, and explore plans to address shortcomings. All the webinar materials are available for download now.

Now Available in Spanish: Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
April 4, 2018 – You can now download a Spanish version of our Training Manual for Treatment Activists: Hepatitis C and HIV Coinfection!

TAGline Spring 2018
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

Now Available in French and Slide Decks Added: Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
March 28, 2018 – You can now download a French version of our Training Manual for Treatment Activists: Hepatitis C and HIV Coinfection, and view or download PDFs of slide decks of every chapter of the English version.

TAG Statement on Final Appropriations for Fiscal Year 2018
March 23, 2018 – TAG lauds Congress on rejecting the President’s anti-science rhetoric.

New York Community Groups Call on City, State, Federal Actors to Increase Funding for Tuberculosis
March 22, 2018 – 
Advocates alarmed that budget cuts led to first rise in TB cases in New York City in over 25 years.

Webinar: “It’s Time to Deliver - Including Pregnant and Lactating Women in Clinical Research"
March 22, 2018 –
Materials from Part II are available now.
 

wb_artists_comp_72dpi_360x262.png

TAG LIMITED ART EDITIONS 1999-2017 Exhibition opened Wednesday March 21, and is running through Saturday March 24 at Westbeth Gallery in New York City. Get the full details here.
 

TAG Applauds Governor Cuomo's Commitment to Eliminate Hepatitis C and Expansion of Enhanced Rental Assistance for People Living with HIV in New York State.
March 16, 2018 – Read the full statement.

Is Shorter Better? Understanding the Shorter Regimen for Treating Drug-Resistant Tuberculosis
March 12, 2018 – Confused about the shorter regimen for treating Multidrug-resistant TB (MDR-TB)? We were too, so we worked with DR-TB STAT on a brief to understand its pros and cons.

ACTION NEEDED: False Hope - Protect Your Right to Safe, Effective Medicines by Stopping the "Right to Try" Movement
March 5, 2018 – The Senate already passed a False Hope bill (The Right to Try Act of 2017), and we anticipate a similar bill will go to the House soon. Many patients need experimental medicines before they're approved, but the U.S. Food and Drug Administration (FDA) already has a very effective mechanism for allowing for early access.

TAG Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy
March 5, 2018 - Antitretroviral therapy is highly effective at suppressing HIV viral load, but for some individuals this does not lead to adequate reconstitution of the immune system. TAG's issue brief offers an overview of suboptimal immune recovery on antiretroviral therapy, and explains why it remains an important concern.

Civil society calls on Novartis to end 'bullying tactics' and respect countries' legal rights to make medicines more affordable
March 1, 2018 – TAG rises in solidarity with 11 civil society organizations around the world in opposing the menacing and obstructive tactics by the pharmaceutical giant, Novartis, which seeks to undermine countries' affordable access to medicines.

Webinar: It's Time to Deliver - Including Pregnant and Lactating Women in Clinical Research, Pt 1
February 21, 2018 – Pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant women as a vulnerable population, among others. Part I of this webinar series was was intended to broaden and build the capacity of civil society and other partners interested in issues related to pregnant and lactating women and research.

NY State Medicaid Director Announces Potential Path for Volume Based Deal to Expand Hepatitis C Treatment at Lower Price
February 16, 2018 –  On Monday, February 12th, New York State Medicaid Director Jason Helgerson made news by announcing a potential path forward in the State’s response to its major hepatitis C epidemic at the joint Senate/Assembly budget hearing on Health and Medicaid.

Statement on POTUS FY19 Budget Release
February 13, 2018 – Treatment Action Group released a statement today in which it vehemently opposes cuts in the Trump administration’s fiscal year (FY) 2019 budget proposal. Those cuts severely threaten the accelerated progress of recent years towards ending the domestic and global HIV/AIDS, tuberculosis (TB) and hepatitis C virus (HCV) epidemics.

Know Your Rights: Tuberculosis Prevention, Diagnosis, and Treatment Guide
February 5, 2018 – We recently released this innovative new guide for people who have tuberculosis (TB), people who are at risk for it, and the people who take care of them.

Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
February 1, 2018 – We've just released an updated Training Manual for Treatment Activists: Hepatitis C and HIV Coinfection. The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment for, hepatitis C virus (HCV).

Letter from Health Organizations: NAFTA Renegotiations Must Not Undermine Access to Affordable Medicines
January 26, 2018 – A group of 97 International, U.S., Canadian, and Mexican health organizations sent this letter to representatives of those countries, asking them to ensure that any North American Free Trade Agreement (NAFTA) renegotiations don’t undermine access to affordable medicines.

Letter to Gilead Sciences Opposing Unethical Patient Assistance Program Policy for Truvada for Postexposure Prophylaxis
January 25, 2018 – Gilead Sciences is limiting access to Truvada as a component of nonoccupational postexposure prophylaxis (nPEP) through its patient assistance program to once in a lifetime, with hardship review criteria and processes for subsequent prescriptions that have not been clearly articulated and are likely a considerable barrier to nPEP by uninsured and underinsured U.S. residents.

Discriminatory Conscience and Religious Freedom Division Proposed Rule Threatens Our Most Vulnerable Communities
January 19, 2018 – TAG is alarmed by recent actions taken by the Trump administration to subvert the health and wellbeing of women, transgender individuals, and marginalized communities in America.

Webinar: Good COPs or Bad COPs? Advocacy to Ensure the Prioritization of TB in 2018 PEPFAR Country Operational Plans (COPs)
January 18, 2018 – Every year, PEPFAR meets to discuss their strategy and budget for the following year, and set targets on implementing country operation plans (COPs) to improve the response to HIV/AIDS. This webinar held on Thursday, January 11 provides key information regarding the PEPFAR COPs process and timelines, TB/HIV services covered by PEPFAR, and what civil society and advocates should prioritize for inclusion in COPs.

TAG Mourns the Loss of Mathilde Krim, PhD
January 16, 2018 – TAG mourns the loss of an inspirational, tireless, catalytic leader of our movement. Dr. Krim understood the gravity of the epidemic, in its earliest and darkest days, and was driven by her own remarkable intelligence, fierce commitment to civil rights and social justice, extraordinary social and political networks, and true grit to galvanize funders, scientists, policy leaders, and activists toward a single cause: ending HIV and AIDS as a threat to humanity.

Securing a Tuberculosis-Free Future through the Visionary Research of the CDC’s Tuberculosis Trials Consortium
January 10, 2018 – CRAG, the community advisory board to the Tuberculosis Trials Consortium has produced a useful new brief to raise awareness of the TBTC’s accomplishments, show major advancements in TB care resulting from TBTC studies, and make the case for increasing TB research funding at CDC.

TAG Joins Call to Oppose U.S. Secretary of Health and Human Services Appointment
January 5, 2018 —In advance of a U.S. Senate Committee on Finance hearing on January 9, 2018, TAG and over 60 other civil society organizations issued a statement asking U.S. senators to oppose the confirmation of Alex Azar as Secretary of Health and Human Services.

Ending the HIV/AIDS Epidemic
December 26, 2017 – We now have evidence-based tools for HIV treatment and prevention that are so effective that they could conceivably end the most deadly infectious disease epidemic in modern history. Many community leaders across the United States are calling for just that: an end to the HIV/AIDS epidemic in their cities, their counties, and their states.

Hasty Passage of the Tax and Health Care Bill
December 22, 2017 – With the hasty passage of the tax and health care bill passed along party lines yesterday afternoon, Congress has sent a clear message on how they prioritize communities living with and vulnerable to HIV, tuberculosis (TB), and hepatitis C virus (HCV) in the upcoming mid-term election year.

TAG Statement on Forbidden Words in Budget Documents
December 20, 2017 – Treatment Action Group (TAG) joins the chorus of rational voices expressing outrage at reports that HHS agencies have received instructions to avoid words unpalatable to the Trump administration in their budget requests.

TAG Statement to Human Rights Council on Human Rights Concerns in the UAE
December 18, 2017
 – On December 13, 2017, TAG participated in a hearing in Geneva, Switzerland to brief members of the Human Rights Council on human rights concerns in the United Arab Emirates (UAE).

Webinar: Exploring the Implications of the Delamanid Phase III and STREAM Trial Results
December 14, 2017
 – The first ever phase III trials for multidrug-resistant TB (MDR-TB) finally yielded results. Treatment Action Group (TAG), ACTION, and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) presented the results in a Webinar held on December 12, 2017.

2017 Symposium: Reframing Risk and Accountability for Action to ZERO TB
December 14, 2017
– On October 12, 2017, in Guadalajara, Mexico, Treatment Action Group, Advanced Access & Delivery, Harvard Medical School, Partners In Health, and the Stop TB Partnership sponsored a symposium in conjunction with the Union World Conference on Lung Health.

HIV Cure Research Information Sheet
December 14, 2017
 – A TAG information sheet on the current state of research into curing HIV infection. 

TAGline Fall 2017
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

Sign the Declaration Calling for Drug Decriminalization to Achieve Hepatitis Elimination
December 4, 2017 – At the World Hepatitis Summit in São Paulo, Brazil, a large coalition of hepatitis patients, representatives of the drug using community, medical providers, researchers, and public health experts expressed their whole-hearted support to the commitment of the World Health Organization (WHO)’s goal to eliminate viral hepatitis by 2030. 

Changing World Health Organization Global TB Program Leadership
December 1, 2017
– TAG's Executive Director, Mark Harrington, congratulates Dr. Mario Raviglione on his retirement and thanks him for his efforts and the years of collaboration while he was director of the World Health Organization’s (WHO's) Global TB Program.

TAGupdate
December, 2017 – TAG's progress on the fight to end HIV/AIDS, viral hepatitis, and tuberculosis.

Suboptimal Immune Recovery on Antiretroviral Therapy: Causes, Consequences, & the Search for Solutions
November 29, 2017 – Video and slides from a webinar presented by TAG's Basic Science, Vaccines and Cure Project Director Richard Jefferys and Nelson Vergel from the Program for Wellness Restoration. 

Remarks by Erica Lessem on TB research at the WHO Global Ministerial Conference on Ending TB
November 27, 2017
– In remarks delivered at the first-ever WHO Global Ministerial Conference on Ending Tuberculosis (TB), TAG's Deputy Executive Director of the TB Project, Erica Lessem, describes the urgent need for civil society to drive political action on funding TB R&D, by drawing from lessons and successes of the HIV movement.

The Ascent Begins: Tuberculosis Research Funding Trends, 2005–2016
November 8, 2017 – Global funding for TB research reached a previously unreported high of $726 million in 2016, according to TAG's latest Tuberculosis Research Funding Trends report. This represents a $100 million increase over 2015 levels and marks the first time annual funding for TB research and development (R&D) has exceeded $700 million since TAG began tracking spending in 2005. Although higher than in previous years, this amount remains woefully inadequate when judged against the innovation gaps holding back the response to TB, which is the world’s leading cause of death from a single infectious agent.

End the Epidemic Resources: Southern States EtE Meeting Summary and FAQs
November 2, 2017 – In May, TAG, the Southern AIDS Coalition, the Southern HIV/AIDS Strategy Initiative, Sisterlove, and AIDS Alabama, and the National Alliance of State and Territorial AIDS Directors (NASTAD) held a consultation with more than 40 community advocates and key stakeholders from across the Deep South to assess the major challenges and opportunities for EtE planning. Several key findings from that meeting can be found in this summary report. Included here is a document addressing the frequently asked questions we often get about the EtE campaigns.
 
Forging A Path to HCV Elimination: Simpler Tests and Affordable Generics
October 31, 2017 – A summary of the July 2017 Hepatitis C World Community Advisory Board meeting on the HCV landscape and the significant barriers—such as financing, awareness, complicated and unaffordable diagnostics, centralized service delivery, and stigma—that obstruct the sustainable scaling up of prevention, testing, and treatment services.
 
US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation
October 27, 2017 – TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
 
Tools to help support activists in engaging national policy makers on TB
October 25, 2017 - Two unprecedented political opportunities are rapidly approaching– the Global Ministerial Conference and the UN High Level Meeting on TB. Civil society and community groups have a critical role to play in raising the profile and understanding of the issues we face in TB among government officials and ensuring that the commitments they make at high-level meetings are translated into urgent investments and actions. To facilitate engagement between civil society and community groups and national policy makers, TAG has created tools and resources to help support grassroots efforts.

Submission to the Office of the United Nations High Commissioner for Human Rights to Report on Sustainable Development Goals and Health
October 16, 2017 – A review of comments submitted by TAG to the Office of the United Nations High Commissioner for Human Rights, in response to a request for submissions from interested organizations and stakeholders for the preparation of its report on Sustainable Development Goals and Health.